Conclusion & Future Perspective
The continued advancement of screening technology is likely to lead to the incorporation of WES or even WGS within newborn screening programs. The management of information generated by these technologies will likely be a focus of research and practice for the foreseeable future. We suspect that wholesale use of genome-level information will remain a promissory goal, but that barriers related to the capacity of healthcare systems – cost, data management, and clinical expertise – as well as patient limitations with respect to the amount of information that can be absorbed, will require the consolidation of information into packages, bins, or other more manageable forms. The practicalities of information management will influence the application of these technologies. We anticipate a concomitant move away from onerous specific consent approaches in which processes and results are provided in intimate detail, to more generic or broad consent approaches grounded in the types of information or general uses to which information and samples will be put.
Financial & competing interests disclosure
This work was supported by funding from the Canadian Institutes of Health Research (CIHR) (EOG-131589). SG Nicholls is supported by a CIHR Postdoctoral Fellowship (Ref: 122403). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Open Access
This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/3.0
Personalized Medicine. 2014;11(6):593-607. © 2014